Research

Featured research

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

A large proportion of early users (36.1%) of oral semaglutide (Wegovy pill) had no prior evidence of GLP-1-based medication use, suggesting rapid uptake among patients new to taking GLP-1 medications. Among patients who previously used a GLP-1-based medication, most...

Truveta Research graphic announcing a Contraception journal study evaluating lidocaine and opioid use during IUD insertion.

Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025

Authors: Nina B. Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen G. Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...

Respiratory virus monitoring report, data through December 2025

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through December 2025 

Respiratory virus–associated hospitalizations increased substantially (+125.3%) in December 2025 and accounted for nearly 7% of all hospitalizations by the last week of the month. This increase was driven primarily by a rise in influenza-associated hospitalizations...

Rising use of GLP-1 medications among women with PCOS

Among women prescribed a semaglutide or tirzepatide medication, the percentage with a PCOS diagnosis increased from 4.6% in 2021 to 5.7% in 2025, a 23.9% relative increase. Nearly all PCOS patients prescribed semaglutide or tirzepatide also had obesity or type 2...